Comparison of Methadone and Morphine in the Treatment of Neonatal Abstinence Syndrome Based on Treatment Duration
| Author | Ali Naseh | en |
| Author | Kosar Noorzadeh | en |
| Author | Ghazaleh Rasti | en |
| Author | Farzaneh Palizban | en |
| Author | Farhad Mansouri | en |
| Author | Marzieh Maddah | en |
| Author | Naeeme Taslimi Taleghani | en |
| Author | Elahe Rastkar Mehrabani | en |
| Author | Sadaf Hasani | en |
| Orcid | Ali Naseh [0000-0001-7258-0815] | en |
| Orcid | Kosar Noorzadeh [0009-0000-7587-7251] | en |
| Orcid | Ghazaleh Rasti [0009-0009-2617-7430] | en |
| Orcid | Farzaneh Palizban [0000-0002-4127-9541] | en |
| Orcid | Farhad Mansouri [0009-0006-2383-5248] | en |
| Orcid | Marzieh Maddah [0000-0002-4186-9584] | en |
| Orcid | Naeeme Taslimi Taleghani [0000-0003-4924-2310] | en |
| Orcid | Elahe Rastkar Mehrabani [0009-0001-3632-6569] | en |
| Orcid | Sadaf Hasani [0009-0008-5358-8422] | en |
| Issued Date | 2026-11-30 | en |
| Abstract | Background: Neonatal abstinence syndrome is a major consequence of in utero opioid exposure. Objectives: This study compared methadone and morphine for controlling NAS and assessed their effects on treatment duration. Methods: This prospective comparative clinical trial with alternating allocation was conducted at Mahdiyeh Hospital in 2024 - 2025. Neonates with a gestational age of ≥ 34 weeks who were diagnosed with NAS were assigned to a treatment group. Pharmacologic treatment was initiated when two assessments performed 3 - 4 hours apart yielded Finnegan scores ≥ 8. Neonates with major congenital anomalies were excluded. Treatment duration was measured until treatment cessation. Results: Of 158 neonates, 89 received methadone (mean treatment duration, 19.3 days; median, 17 days; range, 7 - 50 days), and 69 received morphine (mean treatment duration, 21.2 days; median, 20 days; range, 8 - 51 days). Variability was high in both groups, with standard deviations of 9.1 days for methadone and 10 days for morphine. The unadjusted independent-samples t-test showed that treatment lasted an average of 1.9 days longer in neonates receiving morphine; however, the difference was not statistically significant (P = 0.212). In the primary multivariable analysis, which was adjusted for gestational age, birth weight, milk intolerance, and polysubstance exposure but not phenobarbital use, morphine was associated with an estimated 2.05-day longer treatment duration than methadone; this difference was not statistically significant (β = 2.05 days; 95% confidence interval [CI], −1.29 to 5.40; P = 0.229). In a sensitivity analysis additionally adjusted for phenobarbital use, the estimated treatment effect was attenuated and reversed in direction (β = −0.34 days; 95% CI, −3.70 to 3.01; P = 0.841). None of the covariates in the primary model, including gestational age, was independently associated with treatment duration (P > 0.05). Adjunctive phenobarbital use was associated with longer treatment duration. Sex was not associated with treatment duration and was not retained as a significant predictor. Conclusions: No statistically significant difference in treatment duration was observed between methadone and morphine for NAS. | en |
| DOI | https://doi.org/10.5812/jcp-174053 | en |
| URI | https://brieflands.com/journals/jcp/articles/174053 | en |
| Keyword | Neonatal Abstinence Syndrome | en |
| Keyword | Methadone | en |
| Keyword | Morphine | en |
| Keyword | Opioid Withdrawal | en |
| Keyword | Newborn | en |
| Publisher | Brieflands | en |
| Title | Comparison of Methadone and Morphine in the Treatment of Neonatal Abstinence Syndrome Based on Treatment Duration | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- jcp-17-4-174053-publish-pdf.pdf
- Size:
- 481.37 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF